S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
NASDAQ:YTEN

Yield10 Bioscience (YTEN) Stock Price, News & Analysis

$0.36
-0.01 (-2.96%)
(As of 09:43 AM ET)
Today's Range
$0.35
$0.38
50-Day Range
$0.19
$0.43
52-Week Range
$0.18
$3.29
Volume
207,593 shs
Average Volume
4.55 million shs
Market Capitalization
$4.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Yield10 Bioscience MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
833.1% Upside
$3.50 Price Target
Short Interest
Healthy
2.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Yield10 Bioscience in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

YTEN stock logo

About Yield10 Bioscience Stock (NASDAQ:YTEN)

Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.

YTEN Stock Price History

YTEN Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Why Is Yield10 (YTEN) Stock Up 117% Today?
Yield10 Bioscience Inc.
Yield10 Bioscience just downgraded at Lake Street, here's why
Why Is Yield10 Bioscience (YTEN) Stock Up 34% Today?
Yield10 Bioscience Inc YTEN
See More Headlines
Receive YTEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/27/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:YTEN
Employees
30
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$4.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+833.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-13,570,000.00
Pretax Margin
-9,770.75%

Debt

Sales & Book Value

Annual Sales
$450,000.00
Book Value
$0.89 per share

Miscellaneous

Free Float
10,855,000
Market Cap
$4.49 million
Optionable
Not Optionable
Beta
1.51

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Oliver P. Peoples Ph.D. (Age 66)
    Co-Founder, President, CEO & Director
    Comp: $344.48k
  • Dr. Anthony J. Sinskey Ph.D. (Age 84)
    Sc.D., Co-Founder & Independent Director
    Comp: $62.5k
  • Dr. Kristi D. Snell (Age 56)
    VP of Research & Chief Science Officer
    Comp: $278.69k
  • Ms. Lynne H. Brum (Age 60)
    VP of Planning & Corporate Communications and Secretary
    Comp: $278.69k
  • Mr. Charles B. HaaserMr. Charles B. Haaser (Age 68)
    VP of Finance, Chief Accounting Officer & Treasurer
    Comp: $236.41k
  • Dr. Nicholas Renegar Ph.D.
    Director of Business Analytics & Operations

YTEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Yield10 Bioscience stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" YTEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YTEN, but not buy additional shares or sell existing shares.
View YTEN analyst ratings
or view top-rated stocks.

What is Yield10 Bioscience's stock price target for 2024?

3 analysts have issued twelve-month price objectives for Yield10 Bioscience's shares. Their YTEN share price targets range from $3.00 to $4.00. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 833.1% from the stock's current price.
View analysts price targets for YTEN
or view top-rated stocks among Wall Street analysts.

How have YTEN shares performed in 2024?

Yield10 Bioscience's stock was trading at $0.2393 on January 1st, 2024. Since then, YTEN shares have increased by 56.7% and is now trading at $0.3751.
View the best growth stocks for 2024 here
.

When is Yield10 Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our YTEN earnings forecast
.

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience, Inc. (NASDAQ:YTEN) issued its earnings results on Tuesday, November, 9th. The specialty chemicals company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.16. The specialty chemicals company earned $0.09 million during the quarter, compared to analysts' expectations of $0.22 million. During the same quarter in the previous year, the business posted ($0.87) earnings per share.

When did Yield10 Bioscience's stock split?

Yield10 Bioscience shares reverse split on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Yield10 Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), Advanced Micro Devices (AMD).

How do I buy shares of Yield10 Bioscience?

Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YTEN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners